Diopter Technologies Advances Ocular Disease Treatment with Dissolving Contact Lens

Diopter Technologies has made significant strides in the treatment of ocular surface diseases with its latest innovation, a dissolving amniotic membrane and biopolymer contact lens. This therapeutic device is designed to release growth factors from amniotic-derived materials and dissolve within 48-72 hours, offering a novel approach to eye care that eliminates the need for clinical removal and minimizes the risk of disrupting healing tissues.

The lens's unique features, including sustained growth factor release, a self-dissolving design, and enhanced bioavailability, are tailored to promote epithelial regeneration while reducing inflammation and scarring. Early clinical studies have demonstrated the device's safety and efficacy, with patients reporting improved comfort over a 48-hour wear period compared to traditional silicon hydrogel lenses.

Chris Adams, CEO of Diopter Technologies, emphasized the transformative potential of this device, stating its ability to actively deliver healing factors to the ocular surface represents a significant leap from passive protection to intelligent tissue remodeling. The lens is currently under investigation for its application in treating chemical and thermal injuries, post-refractive surgery care, and chronic dry eye management. With further trials and FDA approval, the company aims to launch the product by Q1 2026.

This development underscores a major advancement in ocular therapeutic delivery systems, merging cutting-edge materials science with clinical ophthalmology to tackle a broad spectrum of eye conditions. For more information on Diopter Technologies and their innovative solutions, visit https://www.dioptertech.com. The potential of this dissolving contact lens to revolutionize the treatment of ocular surface diseases offers hope for patients seeking more effective and comfortable treatment options.